Experience
We recently:
- Served as company counsel in the IPOs of Accretive Health ($138 million), Ameresco ($90 million), AVEO Pharmaceuticals ($90 million), Demandware ($101 million), Durata Therapeutics ($78 million), Merrimack Pharmaceuticals ($105 million), Pacira Pharmaceuticals ($42 million), SS&C Technologies ($185 million), Tangoe ($101 million), Verastem ($63 million) and WhiteWave Foods Company ($391 million)
- Represented Yandex in its $1.435 billion IPO, the largest IPO in history by a search engine company
- Advised clients on numerous follow-on public offerings of equity securities, including those of Alnylam Pharmaceuticals ($93 million), Cynosure ($75 million), Genpact ($580 million), Idenix Pharmaceuticals ($125 million) and Infinity Pharmaceuticals ($88 million)
- Represented clients in many follow-on public offerings of debt securities, including those of Analog Devices ($375 million), Discovery Communications ($5.15 billion), PerkinElmer ($500 million), Staples ($2.0 billion) and State Street ($7.0 billion)
- Handled Rule 144A placements of debt or convertible debt securities for various clients, including Casella Waste Systems ($125 million), Dean Foods ($400 million), The Medicines Company ($275 million), Stream Global Services ($200 million) and Thermo Fisher Scientific ($750 million)
- Acted as underwriters’ counsel in the IPOs of Aegerion Pharmaceuticals ($55 million), Brightcove ($63 million), NuPathe ($50 million), Sensata Technologies ($654 million) and Ubiquiti Networks ($121 million)
- Represented the underwriters in follow-on public offerings of equity or debt securities by Corporación Andina de Fomento ($1.5 billion), Evercore Partners ($178 million), Kenexa ($96 million), Pharmasset ($176 million) and Targacept ($86 million)
Additional public offering and Rule 144A placement experience: 2013, 2012, 2011, 2010, 2009, 2008, 2007, 2006, 2005, 2004, 2003, 2002, 2001, 2000, 1999